3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
12
Gynecologic
5
Head & Neck
4
Genitourinary
4
Thoracic
3
Other
2
Endocrine
2
Tumor-Agnostic
1
Sarcoma
1
Other neoplasm
1
NET
1
Breast
1
Conditions
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
Endometriosis
1
Endometrial Neoplasms
1
Adenomyosis
1
Interventions
Cyclophosphamide
13
Peripheral Blood Stem Cell Transplantation
9
Biopsy
9
fludarabine phosphate
8
Busulfan
8
Whole-Body Irradiation
7
Surveys and Questionnaires
6
Mycophenolic Acid
6
Educational Status
6
Early Intervention, Educational
6
Carboplatin
6
fludarabine
5
Tacrolimus
5
Paclitaxel
5
Methotrexate
5
Methods
5
Melphalan
5
Epoetin Alfa
5
Decitabine
5
Cyclosporine
5
Colposcopy
5
Cisplatin
5
Celecoxib
5
Antilymphocyte Serum
5
Aminolevulinic Acid
5
Sulindac
4
Selenium
4
Radiotherapy
4
Patient Reported Outcome Measures
4
Magnetic Resonance Spectroscopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Robotic Surgical Procedures
×
Other neoplasm
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled